Amsbio is helping researchers fast-track CAR-T cell therapy development with a growing portfolio of experimental cell lines, ...

CAR-T cell therapy has demonstrated remarkable success in treating hematologic malignancies and is now expanding into solid ...

DNA segments that are naturally excised during immune-cell development can replicate, drive damage at various genomic sites and lead to cancer recurrence. Karla K. Rodgers is in the Department of ...

The company has already been testing the autologous cell therapy, LioCyx-M004, in patients with certain liver cancers.

In the largest study of its kind, researchers from The University of Texas MD Anderson Cancer Center identified three subgroups of patients with large B-cell lymphoma (LBCL) who have different levels ...

The firm is restructuring to extend its cash runway and focus resources on clinical programs, including a Phase I CAR T-cell trial in kidney cancer.

A paper published in Cell highlights how researchers have leveraged AI-based computational protein design to create a novel synthetic ligand that activates the Notch signaling pathway, a key driver in ...

Armed with $120 million and a clinical-stage asset, another player is emerging in the increasingly crowded T cell engager (TCE) space. Ouro Medicines launched Friday with the goal of harnessing T ...

The Notch signaling pathway plays a pivotal role in determining cell fate, especially in the development and function of T cells. But mimicking this highly mechanical, contact-dependent pathway in the ...